1st Quarter - Report

KING & SPALDING LLP for AMARIN PHARMA, INC.

Firm
Client
Income
$160,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to patient access to emerging heart disease medications.

Foreign entity interest: Amarin Corporation plc, as identified on the LD-1, has an interest in the issues listed above as the owner of Amarin Pharma Inc.

LobbyistCovered position, as disclosed
DANIEL F DONOVAN Senate Cmtes. on Finance, Small Bus., Gov. Affairs
DAVID JOSEPH FARBER —
CLAUDIA A HRVATIN LD, Rep. Chris Cannon; LA, Rep. John Doolittle

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.